Neuromuscular Disorders

Latest News

Management of MS in Pregnancy Reviewed in UK Guideline

It is important to discuss family planning and pregnancy proactively in women of childbearing age who have multiple sclerosis.

Case Study: Worsening Symptoms While Receiving Interferon Therapy for Multiple Sclerosis

A patient presents for evaluation with painful spasms of the right arm and leg.

Mexiletine Associated With Better Reduction in Muscle Stiffness Than Placebo in Nondystrophic Myotonia

Findings support the efficacy of mexiletine and the potential value of N-of-1 trials for assessing interventions in some chronic rare diseases.

Severe Fatigue Predicts Worsening Disability in Patients With MS

Researchers investigated a link between fatigue and disease worsening in patients with multiple sclerosis.

Movement Disorders Highly Prevalent in Early Multiple Sclerosis

Investigators observed a wide variety of movement disorders — including restless legs syndrome, tremor, and tonic spasms — associated with early demyelinating diseases.

Risk for Conversion of MS Varies With Different Therapies

For relapsing-remitting multiple sclerosis (MS), the risk for conversion to secondary progressive MS is lower with initial treatment with fingolimod, alemtuzumab, or natalizumab versus glatiramer acetate or interferon beta.

Resting-State MEG May Indicate MS-Related Cognitive Decline

Investigators observed a clinically relevant slowing of neuronal activity in patients with MS in the parietotemporal cortical areas and the thalamus significantly associated with cognitive impairment.

Odor Discrimination and Identification Linked to Neurodegeneration in MS

Researchers evaluated patients with MS to determine whether their unique problems with their sense of smell could be due to inflammatory activity or neurodegeneration.

Addressing Cognitive Impairment in Pediatric MS: Expert Q&A

Cognitive reserve may attenuate the impact of MS on cognitive function in some patients.

Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS

Investigators observed that monoclonal antibody ocrelizumab may reduce the risk for upper extremity disability progression in patients with primary progressive multiple sclerosis.